By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



210 Broadway

Cambridge  Massachusetts  02139  U.S.A.
Phone: 1-617-225-2301 Fax: 1-617-225-2503


Algeta is a company focused on developing novel targeted therapies for cancer patients based on its alpha-pharmaceutical platform.

Algeta's lead product radium-223 dichloride is being evaluated as an investigational treatment for castration-resistant prostate cancer patients with bone metastases.

Key Statistics

Ownership: Private

Web Site: Algeta


Company News
Targovax Strengthens Management Team With Algeta Hires 1/22/2015 10:58:09 AM
Bayer AG (BAYN.DE) Clinches $2.9 Billion Deal For Norway's Algeta 2/24/2014 7:14:33 AM
Bayer AG (BAYN.DE) Secures Cancer Firm Algeta With Raised $2.9 Billion Bid 12/19/2013 6:27:51 AM
Bayer AG (BAYN.DE) Bids $2.4 Billion For Norwegian Cancer Drug Partner Algeta 11/26/2013 7:10:59 AM
Algeta to Participate in Upcoming Investor Conferences 11/5/2013 9:33:41 AM
Algeta Release: Net Sales of Xofigo (radium Ra 223 dichloride) Injection for Third Quarter 2013 10/31/2013 12:54:27 PM
Algeta Celebrates the Official Opening of Its Commercial Production Facility for Xofigo® (Radium Ra 223 Dichloride) Injection at the Institute for Energy Technology (IFE) in Norway 6/21/2013 10:22:35 AM
Algeta: New Data and Analyses From Clinical Trials of Xofigo(R) (Radium Ra 223 Dichloride) to be Presented at American Society of Clinical Oncology 5/17/2013 10:34:30 AM
Algeta Results for the First Quarter 2013 5/15/2013 10:58:15 AM
Algeta Schedules First Quarter 2013 Results Presentation, Webcast and Conference Call 5/7/2013 10:20:30 AM